Breaking News
2 hours ago
Vaibhavi M.
Pharma Now Editorial Team
Pharma Now Editorial Team
Chemomab and Scipher Medicine merge in an all-stock deal with $30M in new financing to advance nebokitug into Phase 2 for rheumatoid arthritis, with topline data expected in H1 2028.
Vaibhavi M.
Tarsus Pharmaceuticals acquires iRenix Medical for $75M, adding IRX-101 ocular antiseptic to its pipeline after Phase 2b/3 data showed 50% pain reduction in intravitreal injection patients.
Vaibhavi M.
Aura Biosciences appoints Jeremy Bender to its Board as Bel-Sar advances toward regulatory approval in choroidal melanoma with Phase 3 CoMpass trial enrollment now complete.
Vaibhavi M.
Ipsen's Dysport meets primary endpoints in both E-BEOND and C-BEOND Phase III trials, signaling a likely regulatory submission for a broader migraine indication.
Pharma Now Editorial Team
